FDA Releases Raw Heparin Shipments To Amphastar

Law360, New York (November 11, 2010, 4:49 PM EST) -- The U.S. Food and Drug Administration has agreed to release two shipments of raw heparin from China to Amphastar Pharmaceuticals Inc. amid the generic-drug maker's claims that the agency unlawfully detained them as part of a pattern of vindictive behavior.

The FDA sent a letter to Rancho Cucamonga, Calif.-based Amphastar on Monday saying it would release the two detained shipments of semipurified heparin from a Chinese subsidiary of the drugmaker, pursuant to an exemption in the Code of Federal Regulations, according to Amphastar general counsel Jason...
To view the full article, register now.